Bristol, Gilead collaborate on combining AIDS cocktail into single pill

12/21/2004 | NYTimes.com

Bristol-Myers Squibb and Gilead Sciences formed a joint venture to develop and market a single pill for treating HIV-positive patients, possibly replacing the current regimen requiring a cocktail of two to four drugs a day. The pill the companies hope to market would combine three popular medicines into one tablet, targeted to debut in late 2006. Until now, the two companies have competed in the AIDS drug market. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters he hopes the joint venture is "the beginning of future collaborations."

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN